Novel Markers for the Treatment and Diagnosis of Chronic Lumphocytic Leukemia (CLL)
Technology can be used in the form of a kit for CLL diagnostics.Potential CLL therapy by inhibiting PDE7B, resulting in apoptosis of CLL lymphocytes.
Researchers at UC San Diego have developed a novel technology to diagnose CLL. They have demonstrated an enhanced expression of phosphodiesterase isoform 7B (PDE7B) in lymphocytes of CLL patients. Thus PDE7B can be used as a biomarker for diagnosis and prognosis of CLL.Features of this technology include: PDE7B mRNA and protein levels are increased in CLL patients to up to 70- and 90-fold, respectively.Potential therapeutic agents comprise PDE7B inhibitors, antagonists, and antibodies.
Patent Number: US7846664B2
Application Number: US200896628A
Inventor: Insel, Paul A. | Zhang, Lingzhi | Murray, Fiona | Kanter, Joan R. | Kipps, Thomas | Rassenti, Laura
Priority Date: 7 Dec 2005
Priority Number: US7846664B2
Application Date: 9 Jun 2008
Publication Date: 7 Dec 2010
IPC Current: C12Q000168 | C07H002102 | C07H002104
US Class: 43500612 | 435006 | 5360231 | 53602431 | 53602433
Assignee Applicant: The Regents of the University of California
Title: Diagnosis and treatment of chronic lymphocytic leukemia (CLL)
Usefulness: Diagnosis and treatment of chronic lymphocytic leukemia (CLL)
Summary: The method and kit are useful for diagnosing CLL. The method and composition are useful for treating CLL.
Novelty: Diagnosing chronic lymphocytic leukemia (CLL) comprises comparing the patient's expression level to the expression level of the isoform of PDE associated with CLL in a normal subject
診斷/治療
癌症/腫瘤
7846664
State Of Development Related Materials Intellectual Property Info Patent application (No. 12/960,955) allowance granted. Tech ID/UC Case 19546/2006-052-0 Related Cases 2006-052-0
美國
